Heart Failure, Systolic Clinical Trial
Official title:
Phase I/II Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells in Patients With Post-Myocardial Infarction Heart Failure
This clinical study will utilize allogenic bone marrow-derived culture-expanded MSC that are expanded from the NK1R+ Mesenchymal stem cells as a therapy for chronic ischemic left ventricular dysfunction delivered using the investigational Helix transendocardial delivery catheter.
Chronic heart failure is in need of new therapies. Over the past few years, cardiovascular regenerative medicine using bone marrow-derived cells has emerged as a new treatment strategy that could have tremendous benefit in treating heart failure. At present, several types of adult bone marrow derived stem cells hold great promise to treat heart failure. Allogenic culture-expanded bone marrow-derived human mesenchymal stem cells (MSC) are the subject of the current study as having potential to provide a safe and effective treatment for patients with ischemic heart failure. Mesenchymal stem cells are multipotent stromal cells that can differentiate into a variety of cell types, including osteoblasts (bone cells), chondrocytes (cartilage cells), myocytes (muscle cells) and adipocytes (fat cells which give rise to marrow adipose tissue). The CardiALLO cell therapy is an allogenic bone marrow-derived NK1R+ selected and culture-expanded mesenchymal stem cells that will be delivered intramyocardially using the investigational Helix delivery catheter. The purpose of this study is to determine the safety, optimal dose and efficacy of CardiALLO cell therapy system in patients with post-myocardial infarction heart failure. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT03227393 -
The Effect of Yoga on Cardiac Sympathetic Innervation Evaluated by I-123 mIBG
|
N/A | |
| Recruiting |
NCT04528004 -
Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure
|
Early Phase 1 | |
| Recruiting |
NCT04703842 -
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04522609 -
Electrostimulation of Skeletal Muscles in Patients Listed for a Heart Transplant
|
N/A | |
| Completed |
NCT05475028 -
Network Medicine Approaches to Classify Heart Failure With PReserved Ejection Fraction by Signatures of DNA Methylation and Point-of-carE Risk calculaTors (PRESMET)
|
||
| Not yet recruiting |
NCT06240403 -
Digoxin and Senolysis in Heart Failure and Diabetes Mellitus
|
Phase 2 | |
| Not yet recruiting |
NCT05988749 -
Digital Remote Home Monitoring for Heart Failure
|
N/A | |
| Recruiting |
NCT04950218 -
The Psoriasis Echo Study
|
||
| Suspended |
NCT04701112 -
Acute Hemodynamic Effects of Pacing the His Bundle in Heart Failure
|
N/A | |
| Completed |
NCT03305692 -
ECG Belt vs. Echocardiographic Optimization of CRT
|
N/A | |
| Recruiting |
NCT05933083 -
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
|
N/A | |
| Enrolling by invitation |
NCT03903107 -
The Fluoroless-CSP Trial Using Electroanatomic Mapping
|
N/A | |
| Withdrawn |
NCT04872959 -
TRANSFORM Heart Failure With Reduced Ejection Fraction
|
N/A | |
| Completed |
NCT02920918 -
Treatment of Diabetes in Patients With Systolic Heart Failure
|
Phase 4 | |
| Completed |
NCT02334891 -
Kyoto Congestive Heart Failure Study
|
||
| Recruiting |
NCT03553303 -
Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin
|
Phase 4 | |
| Recruiting |
NCT04083690 -
Multi-lead ECG to Effectively Optimize Resynchronization Devices: New CRT Recipients
|
N/A | |
| Recruiting |
NCT03830957 -
Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker
|
N/A | |
| Recruiting |
NCT06121323 -
Physiological Effects of Lactate in Individuals With Chronic Heart Failure
|
N/A | |
| Completed |
NCT03351283 -
Effect of Sodium Intake on Brain Natriuretic Peptide Levels in Patients With Heart Failure
|
N/A |